Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

24.37 USD +0.63 (+2.65%)
Streaming Delayed Price Updated: 2:41 PM EDT, Apr 20, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,057,416
Open 23.58
Bid (Size) 24.36 (3)
Ask (Size) 24.38 (4)
Prev. Close 23.74
Today's Range 23.52 - 24.50
52wk Range 18.18 - 27.80
Shares Outstanding 311,989,661
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors
Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability,... 
From Business Wire News Releases
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcin
Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line... 
From Business Wire News Releases

Performance

YTD
+18.70%
+18.70%
1 Month
+3.18%
+3.18%
3 Month
+3.31%
+3.31%
6 Month
+7.93%
+7.93%
1 Year
+3.35%
+3.35%

More News

Read More
Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanc
From Business Wire News Releases
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Ur
From Business Wire News Releases
Royalty Pharma Buys Royalty Interest In Cabozantinib Products From GSK
Tags Health Care TAK Contracts
From Benzinga
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
From Business Wire News Releases
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
From Business Wire News Releases
3 Growth Stocks That'll Make You Richer in Q2 (and Beyond)
Tags ZM EXEL Market News
From Motley Fool
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in March
From Business Wire News Releases
June 18th Options Now Available For Exelixis (EXEL)
Tags Stocks
From Market News Video
Sum Up The Parts: IUSG Could Be Worth $101
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]